Last reviewed · How we verify
ARV bitherapie
ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes.
ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes. Used for HIV-1 infection (investigational two-drug regimen).
At a glance
| Generic name | ARV bitherapie |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Antiretroviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This dual-therapy approach combines two antiretroviral agents to inhibit different steps of the HIV replication cycle, reducing viral load and slowing disease progression. The specific agents in this ANRS-developed regimen are selected to provide efficacy while potentially reducing pill burden and adverse event profiles compared to standard triple-therapy regimens.
Approved indications
- HIV-1 infection (investigational two-drug regimen)
Common side effects
- Gastrointestinal disturbances
- Lipid abnormalities
- Hepatotoxicity
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARV bitherapie CI brief — competitive landscape report
- ARV bitherapie updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI